A lot of efforts are made to identify potent and selective inhibitors for the demethylation reactions catalyzed by members of the JMJD2 and JARID1 protein families (1, 2). Both epigenetic eraser enzyme families have been discussed as potential cancer therapeutic targets. In this post, I will review the last releases regarding JMJD2 and JARID1 protein families for assay development and drug discovery applications.
The Histone Demethylase FBXL10 (also known as NDY1, KDM2B, or JHDM1B) has been reported to demethylate histone H3K4me3. By removing active Methyl Epigenetic marks on the chromatin, this “Epigenetic Eraser” thus inactivates gene transcription.